Gontivimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A trivalent nanobody composed of three monovalent Nb017 moieties linked with glycine-serine (GS) linkers, directed against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with potential activity against RSV infections. Upon administration via nebulization and inhalation, gontivimab targets and binds to RSV F protein, neutralizing the virus, and preventing viral entry into host cells. RSV F protein is a small envelope glycoprotein required for cytopathic syncytia formation that results from cell-to-cell fusion.

**Synonyms:** - ALX 0171 - ALX-0171 - ALX0171 - Anti-RSV F Nanobody ALX-0171 - Anti-RSV Protein F Nanobody ALX-0171 - GONTIVIMAB - RSV-specific Nanobody ALX-0171